The Anti-Influenza Virus Drug Favipiravir Has Little Effect on Replication of SARS-CoV-2 in Cultured Cells

• Published in: Antimicrobial agents and chemotherapy Vol. 65; no. 5
• Main Authors: Tomita, Yuriko, Takeda, Makoto, Matsuyama, Shutoku
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 19.04.2021
• Subjects: Letter to the Editor; COVID-19; influenza; SARS-CoV-2; T-705; Avigan; favipiravir; drug

Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.….